RBC Capital lowered the firm’s price target on Regeneron (REGN) to $762 from $779 and keeps a Sector Perform rating on the shares after its Q1 results. Slightly soft Eylea HD were a modest disappointment, though dupi should continue its robust lon-term growth trajectory, while Sanofi (SNY) payoff should step up earnings in the near term, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $917 from $923 at Barclays
- Regeneron Earnings Call Highlights Durable Growth Engine
- These Are the Stocks Reporting Earnings Today – April 29, 2026
- Morning Movers: NXP Semi, Bloom Energy charged up after results
- Regeneron reports Q1 adjusted EPS $9.47, consensus $8.90